Quantum Group completes Phase 1 trial for Lucid-21-302

Quantum BioPharma announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A final safety review committee meeting was held after completion of the trial. The SRC found that Lucid-21-302 was well-tolerated with no safety concerns and no serious adverse events were reported during the trial.